Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence

Autor: Paolo Puccetti, Rita Chiari, Francesca Fallarino, Vanessa Bianconi, Biagio Ricciuti, Giulia Costanza Leonardi, Amirhossein Sahebkar, Matteo Pirro, Sara Baglivo
Rok vydání: 2019
Předmět:
Zdroj: Pharmacology & Therapeutics. 196:105-116
ISSN: 0163-7258
DOI: 10.1016/j.pharmthera.2018.12.004
Popis: Immunotherapy through immune checkpoint blockers (ICBs) is quickly transforming cancer treatment by improving patients' outcomes. However, innate and acquired resistance to ICBs remain a major challenge in clinical settings. Indoleamine 2,3-dioxygenases (IDOs) are enzymes involved in tryptophan catabolism with a central immunosuppressive function within the tumor microenvironment. IDOs are over-expressed in cancer patients and have increasingly been associated with worse outcomes and a poor prognosis. Preclinical data have shown that combining IDO and checkpoint inhibition might be a valuable strategy to improve the efficacy of immunotherapy. Currently, several IDO inhibitors have been evaluated in clinical trials, showing favorable pharmacokinetic profiles and promising efficacy. This review describes the mechanisms involved in IDO-mediated immune suppression and its role in cancer immune escape, focusing on the potential clinical application of IDO inhibitors as an immunotherapy strategy for cancer treatment.
Databáze: OpenAIRE